No one is trashing the study. We can argue if bisantrene is superior to doxorubicin or just equal, but in the current environment if you had a new drug with equal efficacy to SOC and a vastly lower side effect profile you would have a winner.
Despite this “old” data, no clinician is interested in running a modern head to head of bisantrene verses doxorubicin in breast cancer - the future of bisantrene is going to be in combination with doxorubicin, not as a replacement.
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-123
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |